Modelling BET inhibitor resistance in acute myeloid leukaemia [ 2015 - ]

Research Grant

Researchers: Prof Mark Dawson (Principal investigator) ,  Dr brian huntly

Brief description Mutations in epigenetic regulators in AML not only imply a causative role for these proteins in AML but also provide potential targets for therapeutic intervention. One of the most promising epigenetic therapies to have emerged in the last decade are small molecule inhibitors targeted to the Bromodomain and Extra Terminal (BET) family of proteins. This proposal will elucidate the cellular and molecular mechanisms that drive resistance to this new class of drugs

Funding Amount $736,851.00

Funding Scheme Project Grants

Notes Standard Project Grant